In The News

Genentech Presses For Cancer Drug Patent's Invalidation


05 Jan 2017
Reprinted with permission.

In this Law360 article, “Genentech Presses For Cancer Drug Patent's Invalidation”, Michael Jacobs, co-founder and currently co-chair of the firm’s Intellectual Property Practice Group, was quoted about Genentech Inc. urging a California federal judge to invalidate a patent at the center of Phigenix Inc.’s infringement suit targeting Genentech’s breast cancer treatment Kadcyla.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.